CEP-6800

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 406357

CAS#: 609848-02-4

Description: CEP-6800 is a potent PARP inhibitor with potential anticancer activity. CEP-6800 could be used as a chemopotentiating agent with a variety of clinically effective chemotherapeutic agents.


Price and Availability

Size
Price

Size
Price

Size
Price

CEP-6800 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 406357
Name: CEP-6800
CAS#: 609848-02-4
Chemical Formula: C18H15N3O2
Exact Mass: 305.11643
Molecular Weight: 305.33
Elemental Analysis: C, 70.81; H, 4.95; N, 13.76; O, 10.48


Synonym: CEP6800; CEP 6800; CEP-6800.

IUPAC/Chemical Name: 10-(aminomethyl)-4,5,6,7-tetrahydro-1H-cyclopenta[a]pyrrolo[3,4-c]carbazole-1,3(2H)-dione

InChi Key: SDXBGOVSVBZDFL-UHFFFAOYSA-N

InChi Code: InChI=1S/C18H15N3O2/c19-7-8-4-5-12-11(6-8)13-15-14(17(22)21-18(15)23)9-2-1-3-10(9)16(13)20-12/h4-6,20H,1-3,7,19H2,(H,21,22,23)

SMILES Code: O=C1NC(C2=C1C3=C(C4=C2CCC4)NC5=C3C=C(CN)C=C5)=O


Technical Data

Appearance:
yellow solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs

Storage Condition:
0 – 4 C for short term (weeks to 1 month) or -20 C for long terms (months to years).

Solubility:
soluble in DMSO, not soluble in water

Shelf Life:
>2 years if stored properly.

Drug Formulation:
this drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


Additional Information

  
 
 
 


References

1: Guggenheim ER, Ondrus AE, Movassaghi M, Lippard SJ. Poly(ADP-ribose) polymerase-1 activity facilitates the dissociation of nuclear proteins from platinum-modified DNA. Bioorg Med Chem. 2008 Dec 1;16(23):10121-8. doi: 10.1016/j.bmc.2008.09.074. Epub 2008 Oct 14. PubMed PMID: 18977144; PubMed Central PMCID: PMC2662712.

2: Haince JF, Rouleau M, Hendzel MJ, Masson JY, Poirier GG. Targeting poly(ADP-ribosyl)ation: a promising approach in cancer therapy. Trends Mol Med. 2005 Oct;11(10):456-63. Epub 2005 Sep 8. Review. PubMed PMID: 16154385.

3: Miknyoczki SJ, Jones-Bolin S, Pritchard S, Hunter K, Zhao H, Wan W, Ator M, Bihovsky R, Hudkins R, Chatterjee S, Klein-Szanto A, Dionne C, Ruggeri B. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol Cancer Ther. 2003 Apr;2(4):371-82. PubMed PMID: 12700281.